Skip to main content
. Author manuscript; available in PMC: 2019 Apr 1.
Published in final edited form as: Cell Signal. 2018 Jan 10;44:92–102. doi: 10.1016/j.cellsig.2018.01.009

Figure 3. MLN4924 triggers multiple anticancer mechanisms.

Figure 3

1) MLN4924, acting alone, inactivates CRLs by inhibiting cullin neddylation to cause the accumulation of multiple tumor-suppressive substrates, leading to blockage of tumor angiogenesis and inflammatory responses, induction of senescence or apoptosis in cancer cells, and protective autophagy which serves as an overall survival signal to cancer cells. 2) MLN4924, in combination with chemoradiation, sensitizes resistant cancer cells to conventional therapies.